Impax Laboratories Inc

Impax Laboratories — Investor Presentation (January 2008)

27 slides from Impax Laboratories's investor presentation, Jan 9, 2008

  1. Slide 1: IMPAX Laboratories Safe Harbor statement

    IMPAX Laboratories, Inc. (IPXL.PK) "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this presentation contain information that is not historical, these statements are forward-looking in nature and express the beliefs and expecta

  2. Slide 2: 10-K Filing Timeline

    2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q - -------------2005------------- ------------------2006------------------ --------------------2007----------------2008--- 10-K Filing Timeline 2004 Audit

  3. Slide 3: Overview

    Overview Technology-based specialty pharmaceutical company More than 130 R & D experts focused on formulating products that do not infringe on existing patents Generic - Concentration on First-to-File, First-to-Market opportunities Brand - 505 (b)(2) NDA Candidates focused on CNS Significant commerc

  4. Slide 4: Technology and Drug Delivery Capabilities

    Technology and Drug Delivery Capabilities Patented techniques and know-how Patents issued: United States - 7; Foreign - 11 Pending applications: United States - 9; Foreign - 28 Substantial development experience - 109 products approved, pending or under development targeting over $30 billion in US p

  5. Slide 5: R & D Highlights for 2007

    R & D Highlights for 2007 Received 6 FDA approvals Final approvals for generic versions of: Corzide 40/5mg, 80/5mg Ditropan XL 5,10mg Xanax XR 0.5, 1, 2, 3mg Lopid 600mg Persantine Tabs 25, 50, 75mg Baclofen Tabs 10, 20mg

  6. Slide 6: Commercial Highlights for 2007

    Commercial Highlights for 2007 Launched 5 new products Generic versions of: Colestid Tablets 1g Urecholine 5, 10, 25, 50mg Ditropan XL 5, 10mg Corzide 40/5mg, 80/5mg Persantine Tabs 25, 50, 75mg

  7. Slide 7: Formulation Expertise

    Formulation Expertise Applied Technology Candidates Generic Products First-to-File First-to-Market Limited Competition Products Branded Products CNS Products

  8. Slide 8: Technology

    Technology State-of-the art formulation techniques Diverse oral-solid formulation capabilities Targeting products with limited competition Controlled release projects where our substantial experience allows us to formulate around existing patents Specialty formulation projects where we focus on diff

  9. Slide 9: Outsourced Product Development

    Outsourced Product Development Complements (and leverages) internal programs Directed programs 6 offshore companies 17 projects outsourced 5 already submitted and 2 approved

  10. Slide 10: Substantial and Growing Manufacturing Capacity

    Substantial and Growing Manufacturing Capacity Hayward operations 1.2 billion unit annual capacity Taiwan plant underway Phase I - 50% increase Fully approved and operational early 2010

  11. Slide 11: Taiwan Construction

    Taiwan Construction $25 million capital budget All production for export to the US Will be one of only a few FDA approved dosage form plants in Asia

  12. Slide 12: Generic Product Potential

    Generic Product Potential Immediate Release Immediate Release Controlled Release Controlled Release Total Total # Market # Market # Market Pending at FDA 10 $759 12 $8,125 22 $8,884 Under Development 15 $3,332 31 $13,989 46 $17,321 Total 25 $4,091 43 $22,114 68 $26,205 Market - US Market size in mil

  13. Slide 13: Approved

    Approved 4 Jauy 2008 Approved, ' $6,475 Joon ee GD IMPAX 16

  14. Slide 14: Paragraph-IV Generic Products (25 Filings)

    IMPAX Project Generic of* Est. Filing Order** Initial Filing Omeprazole 10,20,40mg DR Prilosec (AZN) 5th of 10 total 4Q99 Bupropion 100,150mg ER Wellbutrin SR (GSK) 3rd of 5 total 2Q00 Bupropion 150mg ER Zyban (GSK) 2nd of 4 total 2Q00 Fenofibrate 67,134,200mg Lofibra (Gate/Teva) 2nd of 2 total 2Q00

  15. Slide 15: Paragraph-IV Generic Products (continued)

    IMPAX Project Generic of* Est. Filing Order** Initial Filing Methylphenidate 18,27,36&54mg ER Concerta (Alza/JNJ) 1st of 2 total 4Q022 Carbidopa/Levodopa ER Sinemet CR (BMS) 2nd of 4 total 4Q02 Carprofen 25,75 &100mg (Vet) Rimadyl (Pfizer) 1st 4Q02 Bupropion 200mg ER Wellbutrin SR (GSK) 1st of 2 tot

  16. Slide 16: Commercial Strategy

    Commercial Strategy Competitive advantages - How we are different Broad-based Approach Multiple commercial outlets in uniquely diverse categories Customer focus Product selection - provide customers with generics that are somewhat unique Equally responsive to near-term customer needs and long-term c

  17. Slide 17: Commercial Strategy: Primary Commercial Outlets

    Commercial Strategy Primary Commercial Outlets: Global Pharmaceuticals Division (Generics) Highly experienced generic field sales organization currently supplying ALL major U.S. generic purchasers Fully integrated internal customer service organization; including electronic commerce (EDI, electronic

  18. Slide 18: Commercial Strategy: Strategic Alliances

    Commercial Strategy - -Strategic Alliances- Supplemental Commercial Outlets: TEVA - 12 products, 9 launched (only 22% of all 41 marketed products) DAVA - Oxycodone (OxyContin) 2nd Marketing period concludes 1/31/08 Opportunistic Only if and when valuable

  19. Slide 19: Generic Sales Capability

    Generic Sales Capability Generic Sales Capability

  20. Slide 20: Brand Projects

    Brand Projects Improved versions of marketed products Same R & D platform Clinical development Focused on CNS Smaller, more concentrated addressable market

  21. Slide 21: VADOVA Value proposition

    VADOVA(tm) Value proposition Potentially higher patient compliance through reduced pill burden Benefits for both the physician and the patient

  22. Slide 22: Branded Products Pipeline

    Branded Products Pipeline IPX056 Under clinical evaluation 2008 estimated enrollment NDA submission target 2009 IPX066 and IPX111 clinical evaluations in 2008/2009

  23. Slide 23: Brand Marketing and Sales

    Brand Marketing and Sales 66 Reps calling on targeted neurologists with Carbatrol (Shire) $39 million funding through 6/2009 Relationships that will facilitate marketing Vadova

  24. Slide 24: Significant Filing Milestones

    Significant Filing Milestones *Includes amendments to two previously filed applications-not included in 2005 applications filed Filing Goal 2008: 8-10 with focus on controlled-release products 2000/ 2001 2002 2003 2004 2005 2006 2007 Applications Filed 16 8 8 6 10 6 6 PPG IV filings 9 5 4 1 3* 1 2 I

  25. Slide 25: Financials

    Financials Dec-06 Mar07 Jun07 Sep 07 Dec-07¢e) ‘én thousands andunausiea) Cash and Investments $ 20,453 $ 47,071 $ 62,451 $142,152 $138,533 Senior Debi $ 540 $ 5375 $ 5310 $ 5244 $ 5,316 Comerible & Sthordinated Debt 75,000 75,000 75,000 75,000 75,000 Subordinated Settlement Obligation 11,000, 10,61

  26. Slide 26: Strong Management Team

    Strong Management Team Larry Hsu, Ph.D., President & CEO 30 years of experience, Abbott Laboratories, co-founded IMPAX David Doll, EVP Commercial Operations 20+ years of experience, Merck and Teva Arthur A. Koch, Jr., SVP, CFO 30 years of experience, Strategic Diagnostics, IBAH Inc., KPMG LLC Charle

  27. Slide 27: Highlights

    Highlights Broad-based drug delivery technology Strong product portfolio "Renewable" Strong management team Brand products offer long-term growth driver

Impax Laboratories — Investor Presentation (January 2008) on 6ix